Sean R. Landman

Sean R. Landman

Auto-generated profile, based on publicly available information

Sean R. Landman

Medtronic Inc, Mounds View, MN (J.K., S.S., N.V., S.M., S.R.L.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
BGBrian Mac Grory
Brian Mac Grory
SLSean R. Landman
Sean R. Landman
PZPaul D. Ziegler
Paul D. Ziegler
CBChantal J. Boisvert
Chantal J. Boisvert
SFShane P. Flood
Shane P. Flood
SYShadi Yaghi
Shadi Yaghi
Background: Central retinal artery occlusion (CRAO) causes sudden, irreversible blindness and is a form of acute ischemic stroke. In this study, we sought to determine the proportion of patients in whom atrial fibrillation (AF) is detected by extended cardiac monitoring after CRAO. Methods: We performed a retrospective, observational cohort study using data from the Optum deidentified electronic health record of 30.8 million people cross-referenced with the Medtronic CareLink database of 2.7 million people with cardiac monitoring devices in situ. We enrolled patients in 3 groups: (1) CRAO, (2) cerebral ischemic stroke, and (3) age-, sex-, and comorbidity-matched controls. The primary end point was the detection of new AF (defined as ≥2 minutes of AF detected on a cardiac monitoring device). Results: We reviewed 884 431 patient records in common between the two databases to identify 100 patients with CRAO, 6559 with ischemic stroke, and 1000 matched controls. After CRAO, the cumulative incidence of new AF at 2 years was 49.6% (95% CI, 37.4%–61.7%). Patients with CRAO had a higher rate of AF than controls (hazard ratio, 1.64 [95% CI, 1.17–2.31]) and a comparable rate to patients with stroke (hazard ratio, 1.01 [95% CI, 0.75–1.36]). CRAO was associated with a higher incidence of new stroke compared with matched controls (hazard ratio, 2.85 [95% CI, 1.29–6.29]). Conclusions: The rate of AF detection after CRAO is higher than that seen in age-, sex-, and comorbidity-matched controls and comparable to that seen after ischemic cerebral stroke. Paroxysmal AF should be considered as part of the differential etiology of CRAO, and those patients may benefit from long-term cardiac monitoring.

15 December 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RKRachel M. Kaplan
Rachel M. Kaplan
PZPaul D. Ziegler
Paul D. Ziegler
JKJodi Koehler
Jodi Koehler
SLSean Landman
Sean Landman
SSShantanu Sarkar
Shantanu Sarkar
RPRod S. Passman
Rod S. Passman
Background: Guideline recommendations for oral anticoagulation (OAC) in patients with atrial fibrillation (AF) are based on CHA 2 DS 2 ‐VASc score alone. Patients with cardiac implantable electronic devices provide an opportunity to assess how the interaction between AF duration and CHA 2 DS 2 ‐VASc score influences OAC prescription rates. Methods and Results: Data from the Optum de‐identified Electronic Health Record data set were linked to the Medtronic CareLink database of cardiac implantable electronic devices. An index date was assigned as the later of 6 months after device implant or 1 year after Electronic Health Record data availability. Maximum daily AF duration (no AF, 6 minutes–23.5 hours, and >23.5 hours) was assessed for 6 months before index date. OAC prescription rates were computed as a function of both AF duration and CHA 2 DS 2 ‐VASc score. A total of 35 779 patients with CHA 2 DS 2 ‐VASc scores ≥1 were identified, including 27 198 not prescribed OAC. Overall OAC prescription rate among the 12 938 patients with device‐detected AF >6 minutes was 36.7% and significantly higher in those with a maximum daily AF duration >23.5 hours (45.4%) compared with those with 6 minutes to 23.5 hours (28.7%). OAC prescription rates increased monotonically with both increasing AF duration and CHA 2 DS 2 ‐VASc score, reaching a maximum of 67.2% for patients with AF >23.5 hours and a CHA 2 DS 2 ‐VASc score ≥5. Conclusions: Real‐world prescription of OAC increased with both increasing duration of AF and CHA 2 DS 2 ‐VASc score. This highlights the need for further research into the role of AF duration, stroke risk, and the need for anticoagulation in patients with devices capable of long‐term AF monitoring.

1 August 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
NANikhil Ahluwalia
Nikhil Ahluwalia
JKJodi Koehler
Jodi Koehler
SSShantanu Sarkar
Shantanu Sarkar
NVNeethu Vasudevan
Neethu Vasudevan
SMShubha Majumder
Shubha Majumder
RSRichard J. Schilling
Richard J. Schilling
BACKGROUND: Atrial fibrillation (AF) events in cardiac implantable electronic devices (CIEDs) are temporally associated with stroke risk. This study explores temporal differences in AF burden associated with HF hospitalization risk in patients with CIEDs. METHODS: Patients with HF events from the Optum de-identified Electronic Health Records from 2007 to 2021 and 120 days of preceding CIED-derived rhythm data from a linked manufacturer’s data warehouse were included. AF burden ≥5.5 h/d was defined as an AF event. The AF event burden in the case period (days 1–30 immediately before the HF event) was considered temporally associated with the HF event and compared with the AF event burden in a temporally dissociated control period (days 91–120 before the HF event). The odds ratio for temporally associated HF events and the odds ratio associated with poorly rate-controlled AF (>110 bpm) were calculated. RESULTS: In total, 7257 HF events with prerequisite CIED data were included; 957 (13.2%) patients had AF events recorded only in either their case (763 [10.5%]) or control (194 [2.7%]) periods, but not both. The odds ratio for a temporally associated HF event was 3.93 (95% CI, 3.36–4.60). This was greater for an HF event with a longer stay of >3 days (odds ratio, 4.51 [95% CI, 3.57–5.68]). In patients with AF during both the control and case periods, poor AF rate control during the case period also increased HF event risk (1.78 [95% CI, 1.22–2.61]). In all, 222 of 4759 (5%) patients without AF events before their HF event had an AF event in the 10 days following. CONCLUSIONS: In a large real-world population of patients with CIED devices, AF burden was associated with HF hospitalization risk in the subsequent 30 days. The risk is increased with AF and an uncontrolled ventricular rate. Our findings support AF monitoring in CIED algorithms to prevent HF admissions.